Cells are constantly on the move, whether in a developing embryo or metastatic cancer. But how do cells adapt to the new ...

MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate stomach problems. PPIs are activated in the acid-producing cells of the ...

Investigators at the Jacobs School of Medicine and Biomedical Sciences have uncovered how heat causes a critical receptor protein within cells to unfold and relay pain, which could open up new ...

Northwestern University researchers have identified structural features in engineered cell receptors that correlate with ...

New research suggests that δ-receptor agonists regulate intestinal motility and relieve abdominal pain in a mouse model of irritable bowel syndrome, potentially offering a novel CNS-targeted ...

Discover the role of phytoestrogens, including soy, in menopause management and breast cancer prevention. Learn how these ...

Excluding people with type 2 diabetes from the trial might have resulted in a missed opportunity to establish whether people with both Parkinson's disease and type 2 diabetes could benefit from GLP-1 ...

Department of Pharmacology and Computational Medicine Program, University of North Carolina−Chapel Hill, Chapel Hill, North Carolina 27599, United States ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online Jan. 16 ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Of those, over 215,000 had been prescribed a glucagon-like peptide-1 (GLP-1) agonist receptor — the class of drugs that includes Ozempic, Wegovy, Mounjaro, Zepbound, and others — and 1.7 ...